CRISPR/Cas Editing Gamma-Globin Regulatory Elements
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemoglobinopathies such as sickle cell disease and beta-thalassemia are limited, with gene therapy and hematopoietic stem cell transplantation carrying risks and uncertainties, and there is a need for improved methods to manage these conditions effectively.
Innovation Solution
CRISPR/Cas-mediated genome editing is used to increase the expression of gamma-globin genes by altering or disrupting gamma-globin gene regulatory elements, such as silencers and promoters, to enhance fetal hemoglobin production, thereby treating beta-hemoglobinopathies by modifying gamma-globin gene regulatory elements using CRISPR/Cas systems to increase gamma-globin gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy or hematopoietic stem cell transplantation is used to treat hemoglobinopathies, then treatment effectiveness is improved, but safety risks and uncertainties increase
Solution Approach 1:
The patent extracts and modifies only the specific regulatory elements (enhancers, silencers, promoters) that control gamma-globin gene expression, rather than introducing entire foreign genes or performing complex stem cell transplantation. This targeted approach using CRISPR/Cas9 to edit specific regulatory sequences reduces the safety risks associated with whole-gene therapy while maintaining the ability to increase fetal hemoglobin production effectively
Solution Approach 2:
The invention applies local quality by making precise, localized modifications to specific regulatory elements within the globin gene cluster. Instead of global genetic modifications, the CRISPR system targets and edits only the necessary enhancer or silencer regions to alter gamma-globin expression levels, thereby achieving treatment effectiveness with minimal disruption to other genetic functions and reduced safety risks
2Productivity
If CRISPR/Cas-mediated genome editing is used to increase gamma-globin expression, then fetal hemoglobin production is enhanced, but the complexity of the treatment method increases
Solution Approach 1:
The patent segments the complex task of increasing fetal hemoglobin production into targeted edits of specific regulatory elements (enhancers or silencers) rather than attempting to modify entire genes or use complex multi-step gene therapy approaches. The CRISPR/Cas9 system delivers guide RNAs and Cas9 protein to specific loci, making discrete modifications to regulatory sequences, which simplifies the overall treatment methodology while achieving enhanced gamma-globin expression
Solution Approach 2:
The invention uses CRISPR/Cas9 as an intermediary tool to achieve the desired increase in fetal hemoglobin production. Rather than directly introducing gamma-globin genes or using complex viral vectors, the CRISPR system mediates precise edits to endogenous regulatory elements, thereby enhancing gamma-globin expression through a controlled, programmable mechanism that reduces treatment complexity compared to traditional gene therapy approaches
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach potentially offers a more effective and safer treatment for hemoglobinopathies by increasing fetal hemoglobin levels, reducing disease symptoms, and improving patient outcomes by targeting and modifying specific regulatory elements within gamma-globin genes.
Implementation Method 1
CRISPR/Cas-mediated genome editing is used to increase the expression of gamma-globin genes by altering or disrupting gamma-globin gene regulatory elements
Data Source
AI summary
Provided herein are CRISPR/Cas-related methods and components for editing a target nucleic acid sequence in a HBG1 and/or HBG2 gene regulatory region, and applications thereof in connection with methods of increasing expression of fetal hemoglobin and treating β-hemoglobinopathies including sickle cell disease and β-thalassemia.